|
KMID : 1143120220120010006
|
|
Asia Pacific Allergy
2022 Volume.12 No. 1 p.6 ~ p.6
|
|
|
Allergen-specific immunotherapy practices and course of coronavirus disease 2019 (COVID-19) in patients during COVID-19
|
|
Erkoc Merve
Ozturk Betul Ozdel
Mungan Dilsad
Oztuna Derya
Bavbek Sevim
Demirel Yavuz Selim
Aydin Omur
Sin Betul Ayse
|
|
|
Abstract
|
|
|
Background: Allergen-specific immunotherapy (AIT) is accepted as the only disease-modifying therapy for IgE-mediated allergic airway diseases and hymenoptera venom allergy. AIT requires repeated contact between patient and physician or nurse in the hospital. Because it is a long-term treatment, compliance is essential issue to obtain maximal efficacy. Coronavirus disease 2019 (COVID-19) pandemic reshaped doctor-patient interaction and pattern of hospital admissions.
Objective: We aimed to determine the possible changes in the administration of AIT and associated factors, in addition to the characteristics of patients diagnosed with COVID-19 infection.
Methods: Adult patients who underwent AIT for hymenoptera venom allergy, allergic rhinitis or allergic asthma between 11 March 2020 and 31 January 2021 were included in our retrospective study. Perennial and preseasonal AIT practices were evaluated. We identified patients with COVID-19 infection among the ones who received AIT.
Results: The mean age of 215 patients was 37.8±11.9 years and 52.1% of the patients were female. In our study, 35.4% of perennial AIT patients did not continue treatment after the COVID-19 pandemic, and the cause was patient-related in 66.7% of the cases. Compliance was 70.7% in patients receiving perennial AIT. The highest compliance rate for AIT was for venom allergy (86.5%). Thirty-four patients (15.8%) were diagnosed with COVID-19 infection. No mortality due to COVID-19 infection was observed in those who underwent AIT.
Conclusion: COVID-19 pandemic has reduced compliance to AIT. Compliance was higher in venom immunotherapy than in aeroallergens. Severe COVID-19 infection and COVID-19 related death were not observed in patients receiving AIT.
|
|
|
KEYWORD
|
|
|
Allergen-specific immunotherapy, Subcutaneous immunotherapy, Venom immunotherapy, Coronavirus disease 2019, Compliance, Adults
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|